Attorney Represents Women Across America in Yaz Injury Lawsuits Against Bayer
NEW YORK, Sep 26, 2011 (BUSINESS WIRE) — The U.S. Food and Drug Administration issued a statement today that the FDA remains concerned, but has not yet reached a conclusion, about the potential increased risk of blood clots from Drospirenone-containing birth control pills such as YAZ, YASMIN, BEYAZ, and OCELLA, among others.
Preliminary results from an FDA-sponsored study of 800,000 women taking birth control pills shows that there is a 1.5 increased risk among Drospirenone-containing pill users.
To address these concerns, the FDA has scheduled an important meeting for December 8, 2011. The FDA will hear testimony concerning these studies and the safety of these medications. The meeting is open to the public.